ATAI Stock Summary and Trading Ideas (Atai Life Sciences N.V. - Common Shares | NASDAQ:ATAI)

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Atai Life Sciences N.V. - Common Shares trades on the NASDAQ stock market under the symbol ATAI.

As of April 18, 2024, ATAI stock price declined to $1.91 with 982,505 million shares trading.

ATAI has a beta of 1.79, meaning it tends to be more sensitive to market movements. ATAI has a correlation of 0.08 to the broad based SPY ETF.

ATAI has a market cap of $316.82 million. This is considered a Small Cap stock.

Last quarter Atai Life Sciences N.V. - Common Shares reported $18,000 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-172,000 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that ATAI belongs to (by Net Assets): IBB, VHT, PSIL, AVSC, GWX.

ATAI has underperformed the market in the last year with a price return of -5.0% while the SPY ETF gained +22.2%. However, in the short term, ATAI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.9% vs +5.2% return in SPY. But in the last 2 weeks, ATAI shares have been beat by the market, returning -23.9% compared to an SPY return of -2.6%.

ATAI support price is $1.86 and resistance is $2.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI stock will trade within this expected range on the day.